Vertex Pharma scientist talks about the long road to developing non
WASHINGTON (AP) — For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone.
Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic.
Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain. Patients taking the drug after surgery experienced more pain relief than those getting a placebo, although the drug didn’t meet a secondary goal of outperforming treatment with an opioid.
The Associated Press spoke with Vertex’s chief scientist Dr. David Altshuler about the company’s research and development plans. The interview has been edited for length and clarity.
Related articles
Chinese FM holds talks with Bolivian counterpart
Chinese Foreign Minister Wang Yi, also a member of the Political Bureau of the Communist Party of Ch2024-04-30Moment police arrest teenager Brian Cohee who hid head of homeless man he murdered in closet
This is the horrifying moment police arrested a 19-year-old who murdered a homeless man and stored h2024-04-30McDonald's praised for innovative ad that smells exactly like classic item on their menu
McDonald's in the Netherlands has launched an innovative new advertising campaign, utlising somethin2024-04-30The Apprentice star Tre Lowe shares Lord Sugar's secret five
The Apprentice star Tre Lowe has shared the inspiring final message he received from Lord Sugar afte2024-04-30English Premier League takes another step toward introducing a spending cap
LONDON (AP) — The English Premier League has taken another step toward introducing a spending cap.At2024-04-30Could this be an answer to YOUR blemish
The skin isn't just your body's largest organ, it's also the most visible. This makes any breakouts2024-04-30
atest comment